Diabetes is a growing global healthcare problem. The majority of people living with diabetes have Type 2 diabetes mellitus (T2DM), characterised by a resistance of the body to the action of insulin. Clinical data suggest that more than 70% of these patients will die of cardiovascular diseases, including heart attack and stroke. Coronary artery bypass graft (CABG) surgery, which typically uses saphenous vein, is the preferred option for improving coronary blood flow in patients with diabetes. However, T2DM patients are vulnerable to vein graft failure following CABG, a phenomenon which may arise from changes in saphenous vein smooth muscle cell behaviour that trigger vascular thickening. We propose that protein O-GlcNAcylation, a glucose-dependent modification that links diabetes with protein function, alters smooth muscle cell behaviour through modification of key proteins. Using cutting-edge biochemical and molecular pharmacological approaches, you will learn to isolate and identify O-GlcNAcylated proteins enriched in smooth muscle cells from T2DM patients and characterise the effects of target protein modification on function.
This is a full time PhD in Medical Sciences.
For informal inquiries, please contact Professor Tim Palmer ([email protected]
Location and Research Culture
Hull York Medical School’s unique partnership brings together the expertise of both the Universities of Hull and York and offers a thriving environment in which to conduct world-leading research. Strong partnerships with NHS Trusts and community health organisations offer a wide clinical base within which to study those conditions which most affect our communities – improving their health while developing research work that can be applied nationally and globally.
The School’s academic and clinical researchers at have a strong reputation for their work, 85% of which is classed as ‘world-leading’ or ‘internationally excellent’ (REF 2014). Their research is advancing improvements in healthcare – treatment, diagnosis and care – improving the health of people locally and impacting national and international health agendas.
The student will join a dynamic research team and thriving community of graduate students from the UK and overseas in the Centre for Atherothrombosis and Metabolic Disease at the University of Hull. Many students also study in our laboratories at local hospitals across the city. This gives our students unparalleled access to the facilities, academic and clinical expertise to thrive in their research. http://www.hyms.ac.uk
Professor Tim Palmer, Chair of Cardiovascular Biology and Director of the Centre for Atherothrombosis and Metabolic Disease. Email: [email protected]
To be arranged upon acceptance of an offer.
In order to qualify for this position, you will require an undergraduate degree with at least a 2.1, or equivalent, in a relevant subject (Biochemistry, Molecular and Cellular Biology, Pharmacology, Pharmacy or related discipline). English Language IELTS 6.5 with a minimum of 6.0 in all components.
How to Apply
All applications MUST be submitted through the HYMS Postgraduate Centre via the online application system: https://www.york.ac.uk/study/postgraduate/courses/apply?course=DRPMEDSMED3&level=postgraduate
Please apply for a “PhD in Medical Sciences” at Hull York Medical School. Please quote HYMS with the scholarship title when applying. In order for the Panel to get a sense of your academic background, commitment and interest, you are required to complete the application form in full and provide a research proposal/outline of academic interest. Research proposals and personal statements may be used in selecting applicants for interview. If you have any queries on how to apply, please email [email protected]
Applicants who are shortlisted for interview will be sent details of the date, time and venue via email. If you are not invited for interview, it means that your application has not been successful. Please note that we do not offer feedback to applicants who are not invited to the interview.